Profile data is unavailable for this security.
About the company
Shanghai Serum Bio-Technology Co Ltd is a China-based company mainly engaged in the research and development of antisera and antitoxins. The Company is mainly engaged in the research, development, manufacturing and sales of preventive and therapeutic drugs in the field of biotoxins and biosafety. The Company's main products include anti-pit viper venom, anti-five-step snake venom, anti-bungi venom, anti-cobra venom, equine immunoglobulin and anti-rabies serum. The Company's products are mainly used for emergency snakebite treatment. The Company mainly conducts its businesses in the domestic market.
- Revenue in CNY (TTM)197.30m
- Net income in CNY50.92m
- Incorporated1999
- Employees321.00
- LocationShanghai Serum Bio-Technology Co LtdNo. 1288, Huaqing Road, Qingpu DistrictSHANGHAI 201707ChinaCHN
- Phone+86 2 164959122
- Fax+86 2 164959122
- Websitehttp://www.serum-china.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Shen Lian Biomedical Corp | 310.36m | -19.73m | 2.28bn | 380.00 | -- | 1.56 | -- | 7.34 | -0.048 | -0.048 | 0.7558 | 3.56 | 0.1944 | 1.16 | 0.9692 | 816,747.00 | -1.48 | 5.39 | -1.58 | 5.84 | 60.66 | 77.45 | -7.62 | 25.48 | 5.14 | -- | 0.0012 | 38.49 | -8.25 | 1.85 | -48.41 | -18.49 | 10.47 | -- |
| Shanghai Serum Bio-Technology Co Ltd | 197.30m | 50.92m | 2.30bn | 321.00 | 45.14 | 2.06 | -- | 11.65 | 0.4706 | 0.4706 | 1.82 | 10.30 | 0.1735 | 1.14 | 3.91 | 614,647.90 | 4.48 | 10.43 | 4.56 | 10.84 | 76.60 | 80.54 | 25.81 | 32.57 | 42.72 | -- | 0.004 | 64.93 | 9.14 | 5.67 | -39.54 | -1.62 | 13.07 | -- |
| Hanshang Group Co Ltd | 1.28bn | -5.18m | 2.39bn | 2.38k | -- | 1.40 | -- | 1.87 | -0.016 | -0.016 | 4.31 | 5.80 | 0.362 | 2.52 | 8.04 | 536,620.30 | -0.4451 | 2.00 | -0.7501 | 3.89 | 53.60 | 57.24 | -1.23 | 4.89 | 0.2688 | 1.18 | 0.3163 | 15.03 | 0.1893 | 5.14 | -32.24 | 25.62 | 12.88 | -- |
Data as of Sep 13 2024. Currency figures normalised to Shanghai Serum Bio-Technology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
2.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Da Cheng Fund Management Co., Ltd.as of 30 Jun 2024 | 323.72k | 1.31% |
| Gfund Management Co., Ltd.as of 30 Jun 2024 | 178.60k | 0.72% |
| E Fund Management Co., Ltd.as of 30 Jun 2024 | 49.77k | 0.20% |
| Truvalue Asset Management Co. Ltd.as of 30 Jun 2024 | 29.30k | 0.12% |
| Fortune & Royal Asset Management Co., Ltd.as of 30 Jun 2024 | 17.70k | 0.07% |
| Hongde Fund Management Co., Ltd.as of 30 Jun 2024 | 14.60k | 0.06% |
| Golden Eagle Asset Management Co., Ltd.as of 30 Jun 2024 | 3.61k | 0.02% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 3.61k | 0.02% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2024 | 3.40k | 0.01% |
| Beixin Ruifeng Fund Management Co., Ltd.as of 30 Jun 2024 | 1.76k | 0.01% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
